In a report issued on April 29, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Ocuphire Pharma (OCUP – Research Report), with a price target of $26.00. The company's shares closed last Friday at $2.34, close to its 52-week low of $2.10. According to TipRanks.com, Caufield is ranked #6714 out of 7877 analysts. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ocuphire Pharma with a $26.00 average price target. See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $7.00 and a one-year low of $2.10. Currently, Ocuphire Pharma has an average volume of 197.8K.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-ocuphire-pharmas-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral